Agent-Driven Validation of Oncology Therapeutic Targets

ABSTRACT Selecting the correct target is critical in drug development, yet systematic replication of published target claims is rarely performed. Here, we introduce a replication-focused AI agent framework to evaluate 31 gene target–disease hypotheses, including context-specific oncology targets from both retracted and non-retracted papers. Each target claim was translated into a zero-shot validation prompt executed by a biomedical research agent in one round, and all agent-driven analyses were validated and scored by domain expert. Compared to retracted targets (2/17 validated, 11.8%), non-retracted targets (9/14 validated, 64.3%) were 17-fold more likely to show context-specific dependency in agent-driven analyses. The replicated targets include WRN in microsatellite stable cancer, PRMT5 in MTAP-deleted cancer, as well as more recent discoveries such as PTGES3, HASPIN, SLC5A3, PKMYT1, FAM126B, and PAPSS1. These results demonstrate that agent-human collaboration can conduct data-driven validation at scale, improve target prioritization, and systematically reduce translational risk for drug development. Competing Interest Statement The authors have declared no competing interest. Footnotes ↵2 Accelerated Discovery with Agents (ADA) Consortium